MetaVia Reports Preclinical DA-1726 Data Showing Comparable Weight Loss to Retatrutide

MetaVia reported preclinical data showing its drug DA-1726 achieved similar weight loss to retatrutide in obese mice, with less food-intake suppression. DA-1726 reduced body weight by 34.2% and 41.7%, compared to 33.7% and 43.6% for retatrutide. The company plans to start a Phase 2 study of DA-1726 in 2027.

Original reporting
Published Nov 16, 2026, 2:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 2:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MetaVia Reports Preclinical DA-1726 Data Showing Comparable Weight Loss to Retatrutide — source image
Decision brief

The 30-second read

$MTVABullishMed
01

Why it matters

The data suggest DA-1726 could be a viable competitor to retatrutide, potentially expanding MetaVia's pipeline value.

02

Market read

First disclosure of promising preclinical data may attract speculative interest in the stock.

03

What to watch

No human data yet; regulatory pathway and competitive landscape remain uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

MetaVia filed an 8‑K reporting early‑stage animal study results for its obesity drug candidate DA-1726.

Company-level read

Ticker impact

$MTVABullishHigh confidence
Context

MetaVia disclosed preclinical data showing its candidate DA-1726 achieved weight‑loss results comparable to retatrutide in obese mice.

Expected impact

potential upside as investors price in promising preclinical results

Evidence & confidence

First‑report of material trial data for a biotech; early‑stage results often trigger speculative buying.

Market effects

May boost interest in obesity‑treatment pipelines and related biotech peers.

Limited to US‑listed biotech investors.

Modest; primarily affects biotech sector sentiment.

Counterpoint

Preclinical efficacy does not guarantee clinical success; investors may remain cautious.

Key entities

  • MetaVia Inc.

    Biotech firm developing obesity therapeutics.

Related articles

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 ​ Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks ​ Positive Part 3B I

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 ​ Statistically Significant Increase in Liver and Circulating FGF21 Expression ​ Greater Glucose Lowering and Comparable Weig

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) presented preclinical data at ObesityWeek 2026, showing its drug DA-1726 increased liver FGF21 expression and achieved weight loss comparable to retatrutide with less food intake suppression. The company plans to start a Phase 2 study for MetALD and ALD in late 2027. DA-1726 demonstrated greater glucose lowering and favorable lipid effects. According to MetaVia, the results support DA-1726's potential in liver-related cardiometabolic diseases.